ARS Pharmaceuticals
SPRY
184 hedge funds and large institutions have $960M invested in ARS Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 58 increasing their positions, 55 reducing their positions, and 21 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
90% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 21
28% more capital invested
Capital invested by funds: $752M → $960M (+$207M)
12% more funds holding
Funds holding: 165 → 184 (+19)
4.37% more ownership
Funds ownership: 73.37% → 77.73% (+4.4%)
5% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 55
41% less call options, than puts
Call options by funds: $2.67M | Put options by funds: $4.54M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$15.8M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$13.2M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$12.4M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$12.1M |
| 5 |
LCS
Levin Capital Strategies
New York
|
+$8.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$11.6M |
| 2 |
State Street
Boston,
Massachusetts
|
-$8.65M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$6.24M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5.07M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$3.59M |
SPRY Hedge Fund Activity: Q1 2025 in Review
184 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q1 2025, worth a combined $960M — up 28% from $752M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new SPRY positions and 21 closed out — a net gain of 19 holders — while 58 added to existing stakes and 55 trimmed.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $15.8M. The largest seller was Alyeska Investment Group, cutting an estimated $11.6M.
- 184 institutional investors held ARS Pharmaceuticals (SPRY) as of Q1 2025, up from 165 in Q4 2024.
- Funds reported $960M of ARS Pharmaceuticals stock for Q1 2025, up 28% quarter-over-quarter.
- 40 funds opened new ARS Pharmaceuticals positions in Q1 2025 and 21 closed out, a net change of +19 holders.
- The largest ARS Pharmaceuticals buyer in Q1 2025 was MPM BioImpact, an estimated $15.8M added.
- The largest ARS Pharmaceuticals seller in Q1 2025 was Alyeska Investment Group, an estimated $11.6M sold.
Based on aggregated 13F filings for Q1 2025.